Stamellou, Eleni
Seikrit, Claudia
Tang, Sydney C. W. http://orcid.org/0000-0002-6862-1941
Boor, Peter http://orcid.org/0000-0001-9921-4284
Tesař, Vladimir http://orcid.org/0000-0001-6982-0689
Floege, Jürgen
Barratt, Jonathan
Kramann, Rafael http://orcid.org/0000-0003-4048-6351
Article History
Accepted: 26 October 2023
First Online: 30 November 2023
Competing interests
: S.C.W.T. has acted as a consultant for Boehringer Ingelheim, Eledon Pharmaceuticals and Travere, and has received speaker’s honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, GSK and Novartis. He is an Executive Committee member of KDIGO. P.B. has received consulting fees from Bristol Myers Squibb, lecture fees from Novo Nordisk, Novartis, Astellas and research funding from Ergonex Pharma GmbH and Affiris AG, but none in association with this work. V.T. has acted as a consultant for or has received honoraria from AstraZeneca, Bayer, Boehringer-Ingelheim, Calliditas, GSK, Novartis, Omeros, Otsuka and Travere. J.F. has acted as a consultant for or has received honoraria from AstraZeneca, Boehringer, Calliditas, Chinook, Novartis, Omeros, Roche, Stadapharm, Travere and Vifor. He was also chair of the data safety monitoring committee of a trial by Visterra. J.B. has acted as a consultant for or has received honoraria from Alnylam, Argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, Galapagos, Novartis, Omeros, Travere Therapeutics, Vera Therapeutics and Visterra; has received grant support from Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Travere Therapeutics and Visterra; and has been involved in the following clinical trials: ADU-CL-19 & ALIGN (Chinook), APPLAUSE (Novartis), ARTEMIS-IGAN (Omeros), ENVISION (Visterra), NefIgARD (Calliditas) and ORIGIN (Vera Therapeutics). His research projects include Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Travere Therapeutics, Visterra. R.K. is a founder, shareholder and board member of Sequantrix GmbH, a member of the scientific advisory board of Hybridize Therapeutics, has received honoraria for advisory boards and talks from Bayer, Chugai, Pfizer, Roche, Genentech, Lilly and GSK and has research funding from Travere Therapeutics, Galapagos, Novo Nordisk and Ask Bio. R.K. was supported by grants from the German Research Foundation (DFG; SFBTRR219: CRU344 428857858 and CRU5011 445703531), by two grants from the European Research Council (ERC-StG 677448, ERC-CoG 101043403), a grant from the Else Kroener Fresenius Foundation (EKFS), the Dutch Kidney Foundation (DKF), TASKFORCE EP1805 and Kolff Grant no. 113351, the NWO VIDI 09150172010072 and a grant from the Leducq Foundation, and the BMBF eMed Consortium Fibromap and the BMBF Consortium CureFib. C.S. has received honoraria from Stadapharm and is supported by the clinical research unit InteraKD consortium CRU5011 (project ID 45703531) of the DFG and by the Dr. Werner Jackstädt Stiftung. E.S. is supported by the clinical research unit InteraKD consortium CRU5011 (project ID 45703531) of the DFG and by STOP-FSGS by the German Ministry for Science and Education (STOP-FSGS-01GM2202C).